This article is more than 5 years old. Information may no longer be current.
Vraylar now available in US for bipolar mania, schizophrenia
Click Here to Manage Email Alerts
Allergan recently announced that Vraylar, a once-daily oral atypical antipsychotic, is now available by prescription in pharmacies throughout the United States.
Vraylar (cariprazine, Forest Laboratories) was approved for treatment of acute manic or mixed episodes of bipolar I disorder and schizophrenia in adults by the FDA in September 2015.
“The important differences in how patients with bipolar I disorder and schizophrenia respond to treatment underscore the need for more treatment options for these serious illnesses,” Gary Sachs, MD, of Massachusetts General Hospital and Harvard Medical School, said in a press release. “The availability of Vraylar gives physicians access to a new treatment option that I think will be appealing to patients who are living with these often devastating conditions.”
Safety and efficacy of Vraylar was established in a clinical trial cohort of more than 2,700 adults with schizophrenia or bipolar mania.
C. David Nicholson
Vraylar will be commercially available in 30-count bottles of 1.5 mg, 3 mg, 4.5 mg and 6 mg dosages, and a 7-count mixed blister pack containing one 1.5 mg and six 3 mg tablets.
“We are excited that Vraylar is now available to the millions of people living with bipolar I disorder and schizophrenia,” C. David Nicholson, PhD, head of brand research and development at Allergan, said in the release. “This launch reinforces Allergan's rich heritage in mental health and our ongoing commitment to developing treatment options that address unmet needs for people who are affected by these serious conditions.”